Expected to open later this year, Children’s Oncology Group’s AALL2331 clinical trial will evaluate a new approach to treating pediatric T-cell blood cancers.
Decades of progress in treating pediatric T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) have resulted in excellent survival rates. But while many patients are cured during their initial treatment, relapse remains one of the greatest challenges for those whose cancer returns.
Treatment for relapsed T-ALL and T-LL is far more difficult, and outcomes are significantly poorer. A new Children’s Oncology Group (COG) Phase 3 clinical trial, AALL2331, aims to change that.
Following years of planning and development, the study is expected to begin enrolling newly diagnosed T-ALL and T-LL patients later this year. Researchers will evaluate whether adding the targeted antibody therapy daratumumab to standard chemotherapy can reduce the risk of relapse while also reducing long-term side effects of treatment.
Building on Decades of Progress
AALL2331 builds on years of research, previous clinical trial success, and an evolving understanding of how T-ALL and T-LL respond to treatment. In a 2024 interview with COG, Dr. David Teachey, Chair of the COG Acute Lymphoblastic Leukemia Committee, described AALL2331 as an important next step in advancing treatment for children with T-cell disease, noting that while immunotherapy has transformed outcomes for B-cell ALL, similar advances for T-cell ALL have proven much more challenging.
That challenge is what AALL2331 is designed to address, and its opening represents the next opportunity to build on that progress.
Why Clinical Trial AALL2331 Matters
Daratumumab is a type of targeted therapy that recognizes a marker found on many T-ALL and T-LL cells. Researchers hope that adding daratumumab to standard chemotherapy will further improve cure rates by reducing the risk of relapse, one of the greatest remaining challenges for children with T-ALL and T-LL.
The study will also examine whether preventive brain radiation, currently used to treat cancer cells that may be “hiding” in or around the brain and spinal cord, can be safely replaced with enhanced chemotherapy without compromising treatment success. Researchers hope this approach could spare children the permanent, irreversible effects brain radiation can have on learning, growth, hormone function, and long-term health.
If successful, the study could help establish a new treatment approach that lowers the risk of relapse, further improves survival rates, and reduces the lifelong impact of treatment.
Asking the Next Important Question in Pediatric Cancer Research
Every advance in pediatric cancer care begins with a carefully designed clinical trial. Each study builds on previous discoveries, helping researchers refine treatments to improve outcomes while reducing lifelong side effects. AALL2331 is the next step in that ongoing process.
The COG Difference
COG’s collaborative research model is designed to turn scientific discoveries into better treatments. Researchers from more than 220 member institutions work together to design, conduct, and refine clinical trials, with each study informing the next.
That collaborative approach has helped establish new standards of care, improve survival, and reduce the long-term effects of treatment for children and adolescents with cancer. AALL2331 continues that tradition of discovery, one carefully designed clinical trial at a time.
As enrollment begins, researchers hope the study will generate evidence that brings children and families one step closer to safer, more effective treatments.
Receive updates on groundbreaking research, scientific discoveries, and the lives they impact.